This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-20 (canceled)

Claim 21 (previously presented): A method of enhancing a cytotoxic T-lymphocyte response in an animal to tumor cells which express low to non-detectable levels of peptide/MHC class 1 complexes on the cell surface comprising:

administering *ex vivo* a nucleic acid sequence encoding a TAP-1 molecule into said tumor cells;

irradiating said tumor cells; and

introducing said tumor cells containing TAP-1 nucleic acid sequences into said animal.

Claims 22-24 (canceled)

Claim 25 (previously presented): The method according to claim 21, wherein the animal is also subjected to surgery, radiation, chemotherapy, immunotherapy or photodynamic therapy.

Claim 26 (previously presented): The method according to claim 21, wherein said introducing step is performed intraperitoneally, intratumorally, subcutaneously, intravenously, orally, mucosally, submucosally or intradermally.

Claim 27 (canceled)

Claim 28 (previously presented): The method according to claim 31, wherein the viral

vector is selected from the group consisting of vaccinia based vectors, adenovirus based vectors, lenti virus based vectors and HSV based vectors.

Claims 29-30 (canceled)

Claim 31 (currently amended): A method of enhancing a cytotoxic T-lymphocyte response in an animal to tumor cells which express low to non-detectable levels of peptide/MHC class 1 complexes on the cell surface comprising:

introducing into the animal, at a location into or near the tumor cell a viral vector encoding a TAP-1 molecule ~~into~~ in a manner which causes uptake by said tumor cells of said viral vector, resulting in the expression of TAP-1 in said tumor cells.

Claim 32 (previously presented): The method according to claim 21, wherein said nucleic acid sequence encodes both the TAP-1 and a TAP-2 molecule.

Claim 33 (previously presented): The method according to claim 31, wherein said viral vector encodes both the TAP-1 molecule and a TAP-2 molecule.

Claims 34-35 (canceled)